OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)Jinlin Hou, Tarik Asselah, Qing Xie et al.|Journal of Hepatology|2024Cited by 8
A randomized, phase Ib trial of recombinant human serum albumin in cirrhotic patients with ascitesXinrui Wang, Yanhang Gao, Qinglong Jin et al.|Hepatology International|2025Cited by 3